A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

Annals of Oncology

Volumn 17, Issue 6, 2006, Pages 990-994

  Theodore, C ^a   Bidault, F ^a   Bouvet Forteau, N ^a   Abdelatif, M ^a   Fizazi, K ^a   di Palma, M ^a   Wibault, P ^a   de Crevoisier, R ^a   Laplanche, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bladder cancer; Chemotherapy; Gemcitabine; Oxaliplatin; Urothelial tract carcinoma

Indexed keywords

CISPLATIN; CREATININE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; OXALIPLATIN; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NORMAL VALUE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; ORGANOPLATINUM COMPOUNDS; PAIN; PAIN MEASUREMENT; PLACEBOS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 33646858090     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl057     Document Type: Article

References (27)

1. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-497.
2. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
3. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989; 142: 289-292.
4. Munoz A, Barcelo JR, Lopez-Vivanco G. Chemotherapy for bladder cancer. N Engl J Med 2003; 349: 2272-2273.
5. Pollera CF, Ceribelli A, Crecco M et al. Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 1994; 5: 182-184.
6. Stadler WM, Kuzel T, Roth B et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394-3398.
7. Moore MJ, Tannock IF, Ernst DS et al. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441-3445.
8. Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, mutticenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
9. Von Der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
10. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19:2638-2646.
11. Carteni G, Dogliotti L, Crucitta E. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol 2003; 22: 384 (Abstr 1543).
12. Raymond E, Chaney SG, Taama A et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998; 10: 1053-1071.
13. Raymond E, Faivre S, Woynarowski JM et al. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998; (2 Suppl 5): 4-12.
14. Faivre S, Le Chevalier T, Monnerat C et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13: 1479-1489.
15. Simon R. How large should a phase II trial be? Cancer Treat Rep 1987; 71: 1079-1085.
16. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis 1978; 31: 557-560.
17. Bajorin OF, Dodd PM, Mamumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 10: 3173-3181.
18. Schemper M, Smith T. A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 1996; 17: 343-346.
19. Culine S, Rebillard X, Iborra F et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: A pilot study. Anticancer Res 2003; 2C: 1903-1906.
20. Font A, Esteban E, Carles J. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Proc Am Soc Clin Oncol 2004; 23: 391 (Abstr 4544).
21. Taieb J, Bonyhay L, Golli L et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules Cancer 2003; 98: 2664-2670.
22. Mavroudis D, Pappas P, Kouroussis C et al. Dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003; 14: 304-312.
23. Linardou H, Aravantinos G, Efstathiou E et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 2004; 64: 479-484.
24. Vaughn DG, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): A trial of the Eastern Cooperative Oncology Group. Cancer 2004; 100: 1639-1645.
25. Meluch A, Greco A, Burris H et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl cancer research network. J Clin Oncol 2001; 19: 3018-3024.
26. Bamias A, Aravantinos C, Deliveliotis D et al. Docetaxel and cisplatin with granulocyte colony stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: A multicenter randomised phase II study from the Hellenic cooperative oncology group. J Clin Oncol 2004; 22: 220-227.
27. de Wit R. European Organisation for research and treatment of cancer: overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 2003; 97 (Suppl 8): 2120-2126.